CLINICAL OUTCOMES TurboHawk Peripheral Plaque Excision System

DEFINITIVE LE Clinical Summary

The DEFINITIVE LE study is one of the largest multinational, multicenter PAD device studies to date, enrolling 800 patients from 47 sites in the United States and Europe. It provides insight into the clinical utility of directional atherectomy with the TurboHawk™ and SilverHawk™ directional atherectomy devices in a broad range of patients, including diabetics, non-diabetics, claudicants, and those with critical limb ischemia (CLI).

Read more about the DEFINITIVE LE clinical study in published, peer-reviewed journals:

DEFINITIVE LE - acute
Acute Results of Directional Atherectomy for the Treatment of Claudication and Critical Limb Ischemia in the DEFINITIVE LE Study

DEFINITIVE LE - primary
Lower Extremity Revascularization Using Directional Atherectomy: 12-month Prospective Results of the DEFINITIVE LE Study

DEFINITIVE LE - infrapopliteal
One-year Outcomes Following Directional Atherectomy of Infrapopliteal Artery Lesions: Subgroup Results of the Prospective, Multicenter DEFINITIVE LE Trial

DEFINITIVE LE - diabetes
A Comparison of Clinical Outcomes for Diabetic and Nondiabetic Patients Following Directional Atherectomy in the DEFINITIVE LE Claudicant Cohort

DEFINITIVE Calcium
Effective Endovascular Treatment of Calcified Femoropopliteal Disease with Directional Atherectomy and Distal Embolic Protection: Final Results of the DEFINITIVE Ca⁺⁺ Trial